Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
What the film says
This trial is for adults with recurrent ovarian or endometrial cancer that is platinum sensitive.
The idea: combine the drug sacituzumab govitecan with the chemotherapy cisplatin, both given by vein. The study sets the best dose of sacituzumab govitecan for use with cisplatin, then expands in ovarian and endometrial cancer groups.
This phase 1 and 2 study plans 54 patients and looks at dose limiting side effects. At the Icahn School of Medicine at Mount Sinai in New York, Amy Tiersten leads it.
Public record; not medical advice.
Sources behind this film
Adults; platinum sensitive recurrent ovarian and endometrial cancer; Sacituzumab govitecan with cisplatin, by vein; Sets optimal dose with cisplatin; expansion in ovarian and endometrial cohorts; Phase 1/2; 54 patients; dose limiting toxicity (+1 more lines)
The drug
Dose 0: Sacituzumab govitecan 7.5 mg/kg Dose -1: Sacituzumab govitecan 5 mg/kg
This is an open-label, Phase 1 study with a dose expansion cohort (DEC), conducted in two separate disease groups (ovarian and endometrial cancer). The primary objective of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
For each disease group, there will be a safety run-in phase utilizing a 3+3 design with a de-escalated dose level if the starting dose shows toxicity and an expansion cohort to evaluate the preliminary efficacy and tolerability of the experimental regimen. The dose expansion cohort will consist of 14 patients in the ovarian cohort and 12 patients in the endometrial cohort with an additional 2 patients in each cohort to account for potential patient replacement.
The study
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.